Prognostic factors impacting survival in early stage uterine carcinosarcoma

Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcoma patients. We performed a retrospective cohort study of women with stage I or II uterine carcinosarcoma at our institution between March 1990 and June 2016. All p...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2019-01, Vol.152 (1), p.31-37
Main Authors: Kurnit, Katherine C., Previs, Rebecca A., Soliman, Pamela T., Westin, Shannon N., Klopp, Ann H., Fellman, Bryan M., Lu, Karen H., Ramondetta, Lois M., Fleming, Nicole D.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Carcinosarcoma - mortality
Carcinosarcoma - pathology
Carcinosarcoma - therapy
Female
Humans
Middle Aged
Neoplasm Staging
Prognosis
Prognostic factors
Retrospective Studies
Treatment
Uterine carcinosarcoma
Uterine Neoplasms - mortality
Uterine Neoplasms - pathology
Uterine Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcoma patients. We performed a retrospective cohort study of women with stage I or II uterine carcinosarcoma at our institution between March 1990 and June 2016. All pathology had been reviewed and confirmed by gynecologic pathologists. Data were extracted from the electronic medical record. Descriptive and comparative statistics were used to compare clinicopathologic characteristics. Univariable and multivariable analyses were performed for survival outcomes. 140 patients were identified. Median age was 67 years (range: 36–91). Median follow-up was 39.1 months (2.9–297.4). The majority of patients had stage IA (67%) versus stage IB (21%) or stage II (11%) disease. The majority of patients (63%) received adjuvant treatment: vaginal brachytherapy only (14%); whole pelvic radiation therapy only (16%); chemotherapy only (n = 13, 9%); combination chemotherapy and vaginal brachytherapy (15%); combination chemotherapy and whole pelvic radiation (9%). 52 patients (37%) received no adjuvant therapy. Median overall survival (OS) was 48.0 months (95% CI 32.7–80.9). On multivariable analysis for OS, advancing age (HR 1.05, 95% CI 1.03–1.08, p 
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2018.10.034